SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalABMD - Replacement Heart System


Previous 10 Next 10 
To: High-Tech East who wrote (106)1/4/2002 3:20:51 PM
From: Logain Ablar
   of 147
 
I came over here since one that stalks me has been pumping this since $30.

From a TA perspective on PnF. Next target will be down in $12 range. [The stalker didn't like my read when it was in the mid 20's either]

stockcharts.com

Fundamently the company sells a product not covered by medical insurance and only acceptable to humans with body frames over $180 pounds (eliminating most of the female population). So while the product is beneficial what is the market $$ potential.

I'd assume by the time they can expand their market and generate revenue other competition will come into play. Like the thigh muscle implants being done in Europe or maybe some other genetic break through (10 years out). This still assumes they can over come the issue of the patient dying due to complications from drugs being taken to minimize rejections (I assume this is the issue only made worse by the poor health of the candidates of the product).

From this perspective I'd say the $12 range won't hold. The one fundamental plus is the balance sheet and cash.

For any in this stock I'd recommend selling now and moving the funds into another company (not biotech @ this time) with a higher probability of recouping your investment.

JMO's & good luck

Share RecommendKeepReplyMark as Last Read


To: High-Tech East who wrote (106)1/14/2002 6:18:46 PM
From: Charles Tutt
   of 147
 
26 is kinda fer 'way fum heer.

Charles Tutt (TM)

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Charles Tutt who wrote (108)1/14/2002 6:44:31 PM
From: High-Tech East
   of 147
 
<<26 is kinda fer 'way fum heer>>

... sho iz ... Charlie ... sho iz

... I'z goin to dat meteor breefen on the 23rd ...

... yuz can c it fo yersef ...

... live via the Abiomed web site ... (you do not have to register for it, just check in here on the 23rd) ...

abiomed.com

... good thing I still have those S&P March puts ... I'm also short the March S&Ps futures since last Friday ... and will probably stay that way through most of the week or more ...

Ken Wilson

Share RecommendKeepReplyMark as Last Read


To: Charles Tutt who wrote (108)1/22/2002 4:07:52 PM
From: High-Tech East
   of 147
 
Charlie ... I think we are getting to the point where ABMD will probably start to make some price progress ...

(1) ... 1st release of an AbioCor patient from a hospital happened in the last few days and some type of conference was held with him today at his hotel in Philadelphia ...

(2) ... big Media Briefing tomorrow (available live via Abiomed.com) ...

(3) ... quarterly earnings report and conference (also live via Abiomed.com) on Thursday ...

(4) ... I bet they are ready to do another whole round of implants very soon ...

(5) ... and European trials could start very soon ... and I think (although I am not positive) that they will include some patients who are not the "sickest of the sick" ... so some patients might go home after only a week or two ... that will be very big whenever that starts to happen, in my opinion ...

Ken

Share RecommendKeepReplyMark as Last ReadRead Replies (3)


To: High-Tech East who wrote (110)2/4/2002 12:21:39 PM
From: Charles Tutt
   of 147
 
It looks to me more like a "crash and burn."

Charles Tutt (TM)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Charles Tutt who wrote (111)1/8/2003 10:29:50 PM
From: Julius Wong
   of 147
 
Eighth AbioCor artificial heart implanted

--------------------------------------------------------------------------------
By Gideon Gil
ggil@courier-journal.com
The Courier-Journal

Nine months since the last implant, University of Louisville surgeons put the eighth AbioCor artificial heart into an ill patient yesterday at Jewish Hospital.

The patient, who was not identified by Jewish Hospital at the request of the patient's family, was "in critical but stable condition," the hospital said in a press release today.

Share RecommendKeepReplyMark as Last Read


To: lindalib who started this subject1/24/2003 7:50:14 AM
From: Julius Wong
   of 147
 
9th patient receives artificial heart
AbioCor implant is second this month at Jewish Hospital
--------------------------------------------------------------------------------
By Gideon Gil
ggil@courier-journal.com
The Courier-Journal

A man who is the ninth recipient of a fully implantable AbioCor artificial heart was in critical but stable condition yesterday after a 10-hour operation Wednesday at Jewish Hospital.

It was the second AbioCor implant in about two weeks at the hospital, after nine months had gone by without any anywhere. Officials of Abiomed, manufacturer of the experimental device, said it demonstrates that the clinical trial is back on track.

courier-journal.com

Share RecommendKeepReplyMark as Last Read


To: High-Tech East who wrote (110)4/14/2003 8:28:42 PM
From: fp_scientist
   of 147
 
Looks like going to zero to me ...

Did you ever consider THOR as an alternative investment to diversify?

fp

Share RecommendKeepReplyMark as Last Read


To: High-Tech East who wrote (110)6/6/2003 12:13:45 PM
From: Lynn
   of 147
 
Any comments about where ABMD is headed now, Ken?

Lynn

Share RecommendKeepReplyMark as Last Read


From: Lynn3/8/2018 6:34:59 PM
   of 147
 
Why Abiomed Soared 14.1% In February



Brian Feroldi, The Motley Fool,
Motley FoolMarch 8, 2018

What happened In response to pumping out record quarterly results and sharing a slew of upbeat news announcements with investors, shares of Abiomed (NASDAQ: ABMD), a medical device maker focused on heart recovery, jumped 14.1% in February according to data from S&P Global Market Intelligence.

So whatAbiomed got off to a fast start in February after it reported strong fiscal third-quarter results:

  • Revenue grew 34% to $154 million.
  • Adjusted net income more than doubled to $32.2 million.
  • Adjusted earnings per share of $0.70 were far higher than the $0.51 that Wall Street had expected.
  • If that wasn't exciting enough, the company also shared two positive regulatory updates with investors later in the month, including:

  • Winning FDA approval for a label expansion claim for its Impella heart pumps to treat heart failure associated with cardiomyopathy leading to cardiogenic shock.
  • Gaining FDA approval for a label expansion claim for certain Impella heart pumps to be used during elective and urgent high risk percutaneous coronary intervention (PCI) procedures.
  • Given the upbeat financial results and label expansion wins, it isn't hard to figure out why Abiomed's shares remain on fire.



    A surgeon in the foreground with an operation happening in background.
    Image source: Getty Images.

    Now whatBetween label expansion claims, product innovations, and international expansion, there are plenty of reasons for investors to believe that Abiomed's days of hyper growth are here to stay. While the company's stock cannot be called cheap right now -- shares are currently trading for more than 22 times sales and 85 times forward earnings -- I still think the long-term potential of this business is so great that the company can continue to put up market-beating results.

    Share RecommendKeepReplyMark as Last Read
    Previous 10 Next 10